{"id":19373,"date":"2023-04-21T22:54:00","date_gmt":"2023-04-21T14:54:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19373"},"modified":"2024-12-23T00:25:22","modified_gmt":"2024-12-22T16:25:22","slug":"healzen-therapeutics-and-neushen-seal-deal-for-global-rights-to-cns-drug-programs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19373","title":{"rendered":"HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs"},"content":{"rendered":"\n

China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on the transfer of rights related to HealZen’s self-developed small-molecule central nervous system (CNS) programs. According to the agreement, NeuShen will secure global exclusive development, regulatory, and commercialization rights to the program, which includes indications for epilepsy, emotional disorders, and more. HealZen Therapeutics will receive an undisclosed amount in upfront and research and development (R&D) milestone payments from NeuShen.<\/p>\n\n\n\n

HealZen Therapeutics’ Commitment to Oncology, Autoimmune, and CNS Diseases<\/strong>
HealZen Therapeutics, dedicated to the treatment of oncology, autoimmune, and CNS diseases, boasts an in-house developed DaMLib class drug fragment library, protein degradation drug DaTProD, and protein rescue drug DaTProS technology platforms. These platforms highlight the company’s expertise in developing novel therapies for CNS conditions.<\/p>\n\n\n\n

NeuShen’s CNS Expertise and Innovation<\/strong>
NeuShen, a CNS specialist with a presence in Shanghai and Boston, is centered around an innovative discovery engine for AAV-based gene therapies and small molecule drug therapies. The company’s focus on CNS treatments aligns with its mission to acquire and advance cutting-edge therapies to address unmet medical needs in this field.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[87,2899,505],"class_list":["post-19373","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-chronic-disease","tag-healzen-therapeutics","tag-neushen-therapeutics"],"yoast_head":"\nHealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on the transfer of rights related to HealZen's self-developed small-molecule central nervous system (CNS) programs. According to the agreement, NeuShen will secure global exclusive development, regulatory, and commercialization rights to the program, which includes indications for epilepsy, emotional disorders, and more. HealZen Therapeutics will receive an undisclosed amount in upfront and research and development (R&D) milestone payments from NeuShen.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19373\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19373\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-21T14:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-22T16:25:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19373#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19373\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs\",\"datePublished\":\"2023-04-21T14:54:00+00:00\",\"dateModified\":\"2024-12-22T16:25:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19373\"},\"wordCount\":206,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Chronic disease\",\"HealZen Therapeutics\",\"NeuShen Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19373#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19373\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19373\",\"name\":\"HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-21T14:54:00+00:00\",\"dateModified\":\"2024-12-22T16:25:22+00:00\",\"description\":\"China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on the transfer of rights related to HealZen's self-developed small-molecule central nervous system (CNS) programs. According to the agreement, NeuShen will secure global exclusive development, regulatory, and commercialization rights to the program, which includes indications for epilepsy, emotional disorders, and more. HealZen Therapeutics will receive an undisclosed amount in upfront and research and development (R&D) milestone payments from NeuShen.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19373#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19373\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19373#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs - Insight, China's Pharmaceutical Industry","description":"China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on the transfer of rights related to HealZen's self-developed small-molecule central nervous system (CNS) programs. According to the agreement, NeuShen will secure global exclusive development, regulatory, and commercialization rights to the program, which includes indications for epilepsy, emotional disorders, and more. HealZen Therapeutics will receive an undisclosed amount in upfront and research and development (R&D) milestone payments from NeuShen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19373","og_locale":"en_US","og_type":"article","og_title":"HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19373","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-21T14:54:00+00:00","article_modified_time":"2024-12-22T16:25:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19373#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19373"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs","datePublished":"2023-04-21T14:54:00+00:00","dateModified":"2024-12-22T16:25:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19373"},"wordCount":206,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Chronic disease","HealZen Therapeutics","NeuShen Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19373#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19373","url":"https:\/\/flcube.com\/?p=19373","name":"HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-21T14:54:00+00:00","dateModified":"2024-12-22T16:25:22+00:00","description":"China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on the transfer of rights related to HealZen's self-developed small-molecule central nervous system (CNS) programs. According to the agreement, NeuShen will secure global exclusive development, regulatory, and commercialization rights to the program, which includes indications for epilepsy, emotional disorders, and more. HealZen Therapeutics will receive an undisclosed amount in upfront and research and development (R&D) milestone payments from NeuShen.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19373#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19373"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19373#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19373"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19373\/revisions"}],"predecessor-version":[{"id":19376,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19373\/revisions\/19376"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}